Huntington's Disease Treatment Market Size (2024 - 2029)

Huntington's Disease Treatment Market Analysis

The Huntington's Disease Treatment Market size is estimated at USD 0.76 billion in 2024, and is expected to reach USD 1.35 billion by 2029, growing at a CAGR of 8.23% during the forecast period (2024-2029).

Huntington’s disease is an inherited disorder that results in the breakdown of nerve cells and impairs brain function. Factors such as the growing burden of Huntington’s disease and the surge in disease awareness levels are the key factors expected to drive the market growth during the forecast period. In addition, the growing efforts from manufacturers to develop effective treatment modalities for the condition are further expected to accelerate market growth.

The significant burden of Huntington’s disease around the globe is anticipated to accelerate demand for effective treatment regimens to manage the increased disease burden. For instance, according to a study published in an article published by the Journal of Huntington's Disease in June 2022, the burden of Huntington’s disease is on the rise in Canada, and there is a significant gap in the effective treatment of the disease.

The significant disease burden and unmet treatment needs are expected to create lucrative growth opportunities for market participants. This is expected to drive the development of advanced treatment options for the disease and stimulate market growth during the forecast period.

In addition, the increased efforts to develop promising treatments for all stages of Huntington’s disease and positive topline results from those investigational treatments are expected to support market growth during the forecast period. For instance, according to an article published by Pharmaceuticals in October 2023, several effective disease-modifying and symptomatic therapies paved their way through clinical trials to manage Huntington’s disease. In addition, these therapies promoted neurogenesis while improving brain function. Significant research and development efforts will likely foster industry expansion during the forecast period.

Moreover, the presence of a high volume of investigational candidates in the late phase of clinical trials and their anticipated launch during the forecast period is further likely to propel industry uptake. For instance, according to June 2024 data from the Clinical Trial Gov, there were around 69 studies in Phase II of the clinical trial, followed by 25 studies in Phase III. Thus, much higher volumes of investigational candidates and their projected launches during the forecast period are further expected to expedite industry expansion.

Also, several strategic initiatives market participants undertake to strengthen their business avenues are further expected to spur industry expansion during the forecast period. For instance, in April 2024, Skyhawk Therapeutics and Ipsen formed a collaboration agreement to develop small molecules that modulate RNA for rare neurological diseases, including Huntington’s disease.

In addition, positive topline results from investigational studies are further expected to propel market growth during the forecast period. For instance, in December 2023, uniQure NV published the results from the Phase I/II clinical trials of AMT-130 to manage Huntington’s disease. The overall results were very promising and showed disease stability in patients. Thus, such ongoing developments will likely accelerate market growth during the forecast period.

Thus, the surge in the burden of Huntington’s disease, increased demand for effective disease treatment, and growing research activities are expected to accelerate industry expansion during the forecast period. However, the high cost of developing effective treatment is expected to hamper the market's growth during the forecast period.

Huntington's Disease Treatment Industry Segmentation

As per the scope of this report, Huntington's disease treatment covers various treatment modalities that are commercially available. It is a genetic disorder that mostly occurs between 30 and 50 years, leading to the degeneration of nerve cells in the brain.

The Huntington's disease treatment market is segmented by type and end user. By type, the market is segmented as symptomatic treatment and disease-modifying therapies. By end user, the market is segmented as hospital pharmacies, retail pharmacies, and online pharmacies. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.